The cutting edge: Promising oncology radiotracers in clinical development - 28/09/24
Highlights |
• | Fibroblast-activation protein-targeted agents respond to the tumor microenvironment and may be equivalent to or better than fluorodeoxyglucose for cancer imaging. |
• | Carbonic anhydrase IX inhibitors help characterize renal masses on positron emission tomography/computed tomography. |
• | Pentixafor targets C-X-C chemokine receptor 4 and may detect low-grade lymphomas and multiple myeloma on positron emission tomography/computed tomography. |
• | Meta-fluorobenzylguanidine may identify adrenoceptor-bearing tumors on positron emission tomography/computed tomography better than existing gamma-imaging agents. |
Abstract |
Molecular imaging moves forward with the development of new imaging agents, and among these are new radiotracers for nuclear medicine applications, particularly positron emission tomography (PET). A number of new targets are becoming accessible for use in oncologic applications. In this review, major new radiotracers in clinical development are discussed. Prominent among these is the family of fibroblast-activation protein-targeted agents that interact with the tumor microenvironment and may show superiority to 2-deoxy-2-[18F]fluoro-d-glucose in a subset of different tumor histologies. Additionally, carbonic anhydrase IX (CAIX) inhibitors are directed at clear cell renal cell carcinoma, which has long lacked an effective PET imaging agent. Those CAIX agents may also have utility in hypoxic tumors. Pentixafor, which binds to a transmembrane receptor, may similarly allow for visualization by PET of low-grade lymphomas, as well as being a second agent for multiple myeloma that opens theranostic possibilities. There are new adrenergic agents aimed at providing a PET-visible replacement to the single-photon-emitting radiotracer meta-[123I]iodobenzylguanidine (MIBG). Finally, in response to a major development in oncologic chemotherapy, there are new radiotracers targeted at assessing the suitability or use of immunotherapeutic agents. All of these and the existing evidence for their utility are discussed.
Le texte complet de cet article est disponible en PDF.Keywords : Carbonic anhydrase IX inhibitor, Fibroblast activation protein inhibitor, Immunotherapy, Oncology, Pentixafor
Abbreviations : CAIX, CTLA-4, CXCL12, CXCR4, DOTATATE, DOTATOC, FDG, FDOPA, FAP, FAPI, HER2, MFBG, MIBG, PARP, PD1, PD-L1, PET, RCC, SPECT, VEGF
Plan
Vol 105 - N° 10
P. 400-406 - octobre 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?